A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of BCI 838 in Healthy Adult Subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
详细描述
This study will evaluate the safety and tolerability following oral administration of multiple doses of BCI-838 in healthy male and female subjects. The pharmacokinetic profile of multiple oral doses of BCI-838 in healthy male and female subjects will also be assessed. In addition, the pharmacodynamic effects of BCI-838 on the central nervous system using quantitative electroencephalogram analysis will be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult male and female healthy volunteers, 18-55 years of age
- •Body Mass Index (BMI) between 18.0 to 30.0 kg/m2 inclusive
- •Female subjects must have a negative pregnancy test at screening and admission. Females of childbearing potential (not at least 2 years postmenopausal or surgically sterile) must be using a reliable, medically acceptable form of contraception for at least 30 days prior to the screening visit and must agree to continue such use throughout the duration of the study and for 3 months after the final dose of study drug.
- •Good general health as determined by medical history and physical examination with no clinically significant medical findings and no clinically relevant medical or surgical history and no acute or ongoing conditions within the past 30 days
- •Able to participate and willing to give written informed consent and to comply with the study restrictions
排除标准
- •Clinically significant medical abnormality, chronic disease or history or presence of significant pulmonary, gastrointestinal, metabolic, cardiac, hepatic, renal or neurological disorder
- •History or current use of alcohol abuse or drug addiction
- •Participation in a drug study within 60 days prior to drug administration.
- •Participation in more than 3 other drug studies in the 10 months preceding the start of this study
- •Donation or blood loss of more than 50 mL of blood within 60 days prior to the first drug administration. Donation of more than 1.5 liters of blood in the 10 months preceding the start of this study
- •Illness within 5 days prior to drug administration
研究组 & 干预措施
BCI-838 Dosing Arm 1
Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
干预措施: BCI-838 (Drug)
BCI-838 Dosing Arm 2
Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
干预措施: BCI-838 (Drug)
BCI-838 Dosing Arm 3
Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
干预措施: BCI-838 (Drug)
结局指标
主要结局
Safety
时间窗: 14 days
Safety will be evaluated by adverse events, vital signs, ECG, clinical labs, and physical exam.
次要结局
- Cmax, tmax, t1/2 , AUC, CL/F, Vz/F, and Kel of BCI-838 and BCI-632(predose, at specified timepoints during the 7-day dosing period, and at Day 10 (72 hours post-dose))
- Quantitative EEG (qEEG) assessments(predose, and at specified timepoints during the 7-day dosing period)